Modello di glucosio nelle donne sterili che ricevono una riproduzione assistita mediante monitoraggio continuo del glucosio
Modello di glucosio nelle donne sterili che ricevono una riproduzione assistita: uno studio prospettico che utilizza il monitoraggio continuo del glucosio
No studies have been seen on glucose variation during medication for assisted reproduction. The aim of this study is to continuously observe glucose variation during assisted reproduction treatment using continuous glucose monitoring (CGM), and to further explore whether glucose variation will affect the outcomes related to assisted reproduction.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
Infertility is a growing global health concern and affects approximately 20% of couples of reproductive age. As a result, the use of assisted reproductive technologies (ART) is becoming more prevalent. This study could serve as a basis for the interpretation of glucose levels with respect to these people undergoing ART regimen. Moreover, the success rate of ART still needs to be further improved. Key challenges include optimizing the hormonal components of ART regimens and determining the ideal treatment duration. This study might provide insights into the potential benefits of monitoring glucose levels at specific points during ART cycles (which is not usually performed in routine practice) and help clinicians tailor ART regimen to minimize glucose variation, ultimately improving clinical pregnancy and live birth rates. Additionally, the findings might support integrating CGM into the clinical practice of ART, enhancing individualized patient care.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Cina, 200233
- Shanghai Sixth People's Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Informed consent and voluntary participation in this study;
- Age ≥ 18 years and ≤40 years old;
- Infertile patients who will undergo their first or second cycle of in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) at the study center;
- The chosen ovulation promotion regimens is the GnRH antagonist regimen/progesterone-promoting ovulation under hyperprogesterone state (PPOS) regimen.
Exclusion Criteria:
- Recent infections (excluding viral infections of the reproductive system such as HPV);
- Recent glucocorticoid treatment or chemotherapy;
- Clinical conditions affecting the outcome of assisted reproduction, including repeated implantation failure, recurrent spontaneous abortion, history of unilateral oophorectomy, uterine malformations, and parental karyotype abnormalities;
- Participants were unable to tolerate tape adhesive around sensor placement area, or with medically documented allergy towards the adhesive (glue) of plasters, or with serious skin diseases (e.g. psoriasis vulgaris, bacterial skin diseases) around sensor placement area.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Altro
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: wearing continuous glucose monitorings
Patients will wear two FreeStyle Libre Pro Flash CGM (Abbott Diabetes Care, Alameda, CA, USA) to ensure continuous tracking of blood glucose levels at key time points throughout the ovarian stimulation. |
Each patient will participate in the group only once and wear two FreeStyle Libre Pro Flash CGM (Abbott Diabetes Care, Alameda, CA, USA), which record glucose readings for up to 14 days. Following the initial consultation and before initiating the ovulation induction protocol, the first CGM sensor will be placed to collect baseline data. Upon entering the ovulation induction cycle, patients will return to the hospital on the 2nd or 3rd day of menstruation, at which point the first CGM sensor will be removed, and the second sensor will be applied. This second sensor will be removed after 14 days. In summary, this protocol ensures continuous tracking of blood glucose levels at key time points throughout the ovarian stimulation. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Mean sensor glucose (MSG)
Lasso di tempo: Through study completion (during assisted reproductive treatment period,about 2 months)
|
Mean of daily continuous 24-h blood glucose |
Through study completion (during assisted reproductive treatment period,about 2 months)
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
time in tight range(3.9~7.8mmol/L, %)
Lasso di tempo: Through study completion (during assisted reproductive treatment period,about 2 months)
|
Percentage of time within glucose level of 3.9-7.8 mmol/L (70-140 mg/dL) measured by CGM |
Through study completion (during assisted reproductive treatment period,about 2 months)
|
|
Time below range (<3.9mmol/L, %)
Lasso di tempo: Through study completion (during assisted reproductive treatment period,about 2 months)
|
Percentage of time below glucose level of 3.9 mmol/L (70 mg/dL) measured by CGM. |
Through study completion (during assisted reproductive treatment period,about 2 months)
|
|
Time above range (>7.8mmol/L, %)
Lasso di tempo: Through study completion (during assisted reproductive treatment period,about 2 months)
|
Percentage of time above glucose level of 7.8 mmol/L (140 mg/dL) measured by CGM |
Through study completion (during assisted reproductive treatment period,about 2 months)
|
|
Coefficient of variation (CV)
Lasso di tempo: Through study completion (during assisted reproductive treatment period,about 2 months)
|
Standard deviation divided by mean glucose level measured by CGM |
Through study completion (during assisted reproductive treatment period,about 2 months)
|
|
Standard deviation (SD)
Lasso di tempo: Through study completion (during assisted reproductive treatment period,about 2 months)
|
Standard deviation of blood glucose measurements during CGM |
Through study completion (during assisted reproductive treatment period,about 2 months)
|
Altre misure di risultato
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Number of oocytes retrieved
Lasso di tempo: Through study completion (during assisted reproductive treatment period,about 2 months)
|
The number of oocytes obtained under ultrasound guidance |
Through study completion (during assisted reproductive treatment period,about 2 months)
|
|
Oocyte retrieval rate
Lasso di tempo: Through study completion (during assisted reproductive treatment period,about 2 months)
|
Oocyte Retrieval Rate = Number of Oocytes Retrieved / Number of Follicles |
Through study completion (during assisted reproductive treatment period,about 2 months)
|
|
Number of MII oocytes
Lasso di tempo: Through study completion (during assisted reproductive treatment period,about 2 months)
|
The number of metaphase II oocytes that have nuclear maturity at the time of injection |
Through study completion (during assisted reproductive treatment period,about 2 months)
|
|
Rate of MII oocytes
Lasso di tempo: Through study completion (during assisted reproductive treatment period,about 2 months)
|
the proportion of oocytes that have nuclear maturity at the time of injection |
Through study completion (during assisted reproductive treatment period,about 2 months)
|
|
Rate of high-quality embryos
Lasso di tempo: Through study completion (during assisted reproductive treatment period,about 2 months)
|
the proportion of Day 2 and Day 3 embryos with high score or grade |
Through study completion (during assisted reproductive treatment period,about 2 months)
|
|
Biochemical pregnancy rate
Lasso di tempo: Through study completion (during assisted reproductive treatment period,about 6 months)
|
The proportion of pregnancies confirmed by the detection of hCG in serum or urine, but without ultrasound confirmation of a gestational sac or fetal heartbeat. |
Through study completion (during assisted reproductive treatment period,about 6 months)
|
|
Clinical pregnancy rate
Lasso di tempo: Through study completion (during assisted reproductive treatment period,about 6 months)
|
The proportion of pregnancies confirmed by ultrasonographic visualization of one or more gestational sacs or definitive clinical signs of pregnancy |
Through study completion (during assisted reproductive treatment period,about 6 months)
|
|
Miscarriage rate
Lasso di tempo: Through study completion, about 1 year
|
The proportion of pregnancies that end spontaneously before 28 weeks of gestation after confirmation of clinical pregnancy |
Through study completion, about 1 year
|
|
Live Birth Rate
Lasso di tempo: Through study completion, 18 months
|
The proportion of successful deliveries resulting in a live-born infant. |
Through study completion, 18 months
|
Collaboratori e investigatori
Sponsor
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- 20250303
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .